相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis
Lauren Young et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2012)
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
T. -F. Tsai et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
Atsuyuki Igarashi et al.
JOURNAL OF DERMATOLOGY (2012)
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis
David M. Pariser et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis A Comprehensive Analysis of All Adalimumab Exposure in All Clinical Trials
Craig Leonardi et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2011)
Reversible Posterior Leukoencephalopathy Syndrome in a Patient Treated With Ustekinumab Case Report and Review of the Literature
David Gratton et al.
ARCHIVES OF DERMATOLOGY (2011)
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Carlos G. Grijalva et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
Tsen-Fang Tsai et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
Erin G. Harper et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Antonella Di Cesare et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells
Michelle A. Lowes et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interieukin-12/23 monoclonal antibody in subjects with plaque psoriasis
Alice B. Gottlieb et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Risk of myocardial infarction in patients with psoriasis
Joel M. Gelfand et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides
Spencer C. Liang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Current concepts - Basal-cell carcinoma.
AI Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris
E Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Biological therapies in the systemic management of psoriasis: International Consensus Conference
W Sterry et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis
CL Kauffman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
分享论文
